Department of Gynecologic Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Department of Medicine, Université de Montréal, Montreal, Quebec, Canada.
Int J Gynecol Cancer. 2021 Jan;31(1):78-84. doi: 10.1136/ijgc-2020-001797. Epub 2020 Oct 30.
Historically, radical hysterectomy followed by adjuvant radiotherapy has been offered to patients with endometrial cancer who have gross cervical involvement; however, this approach is known to carry considerable morbidity. Neoadjuvant radiotherapy followed by extra-fascial hysterectomy has been proposed as an alternative treatment but has been poorly studied to date.
To evaluate the locoregional control rate associated with neoadjuvant radiotherapy followed by extra-fascial hysterectomy.
A retrospective cohort study of 30 patients with endometrial cancer with gross cervical involvement treated between May 2006 and January 2016 was performed. Eligible patients were those aged 18 years with non-metastatic endometrial adenocarcinoma and gross cervical disease treated with curative intent at the Centre hospitalier de l'Université de Montréal. Treatment protocol consisted of pelvic neoadjuvant radiotherapy and high-dose rate brachytherapy followed by extra-fascial hysterectomy. Kaplan-Meier curves were used for survival analysis.
The median age was 60 (range 37-82) and median body mass index was 32 kg/m (range 16-55). Twenty-four (80%) patients were diagnosed with a positive cervical/endocervical biopsy. Clinical staging confirmed 36.7% (n=11) as stage II, 20% (n=6) stage IIIB, 30% (n=9) stage IIIC1, and 13.3% (n=4) stage IIIC2. Seventy-seven per cent (n=23) of patients had an endometrioid histology. Locally advanced disease was identified by imaging alone in six patients. Rates of parametrial, adnexal, vaginal, and nodal invasion were 10% (n=3), 6.7% (n=2), 13.3% (n=4), and 43.3% (n=13) at diagnosis, respectively. All patients completed pelvic radiotherapy (13.3% extended field) and 90% received brachytherapy. Twenty per cent (n=6) of surgeries were performed using minimal invasive technique. On surgical specimen, 63.3% (n=19) had complete cervical response, 90% (n=27) had negative margins, and 10% (n=3) had residual nodal involvement. Median follow-up time was 62 months (range 1-120). Six recurrences were identified; all except one involved distant failure, and two with locoregional failure. Five-year locoregional control rate, disease-free, overall, and disease-specific survival were 90.5%, 78.5%, 92.6%, and 96.2%, respectively. Two patients (6.7%) had grade 3+ acute radiation-related complications (all grade 3). Grade 3+ post-operative morbidity was noted in 2 (6.7%) patients.
Neoadjuvant radiotherapy followed by extra-fascial hysterectomy offers good locoregional control with low treatment-related morbidity in patients with endometrial cancer with overt cervical involvement.
历史上,对于宫颈广泛受累的子宫内膜癌患者,常采用根治性子宫切除术加辅助放疗;但这种方法的并发症发生率较高。新辅助放疗后行筋膜外子宫切除术已被提出作为一种替代治疗方法,但迄今为止研究甚少。
评估新辅助放疗后行筋膜外子宫切除术的局部区域控制率。
对 2006 年 5 月至 2016 年 1 月期间在蒙特利尔大学医疗中心接受治疗的 30 例宫颈广泛受累的子宫内膜癌患者进行回顾性队列研究。符合条件的患者为年龄 18 岁、非转移性子宫内膜腺癌、宫颈疾病肉眼可见且以治愈为目的的患者。治疗方案包括盆腔新辅助放疗和高剂量率近距离放疗,然后行筋膜外子宫切除术。采用 Kaplan-Meier 曲线进行生存分析。
中位年龄为 60 岁(范围 37-82 岁),中位体重指数为 32kg/m2(范围 16-55kg/m2)。24 例(80%)患者的宫颈/颈管活检为阳性。临床分期证实 36.7%(n=11)为 II 期,20%(n=6)为 IIIB 期,30%(n=9)为 IIIC1 期,13.3%(n=4)为 IIIC2 期。77%(n=23)的患者为子宫内膜样组织学。6 例患者仅通过影像学检查发现局部晚期疾病。在诊断时,宫旁、附件、阴道和淋巴结侵犯的发生率分别为 10%(n=3)、6.7%(n=2)、13.3%(n=4)和 43.3%(n=13)。所有患者均完成了盆腔放疗(13.3%的患者采用扩展野放疗),90%的患者接受了近距离放疗。20%(n=6)的手术采用微创技术进行。在手术标本中,63.3%(n=19)宫颈完全缓解,90%(n=27)切缘阴性,10%(n=3)淋巴结残留。中位随访时间为 62 个月(范围 1-120 个月)。共发现 6 例复发,除 1 例外均为远处失败,2 例为局部区域失败。5 年局部区域控制率、无病生存率、总生存率和疾病特异性生存率分别为 90.5%、78.5%、92.6%和 96.2%。有 2 例(6.7%)患者出现 3 级以上急性放射性相关并发症(均为 3 级)。有 2 例(6.7%)患者出现 3 级以上术后并发症。
对于宫颈广泛受累的子宫内膜癌患者,新辅助放疗后行筋膜外子宫切除术可获得良好的局部区域控制效果,且治疗相关的并发症发生率较低。